You are here: Industry Insights > Market News > Marksans Pharma recalls 11,279 bottles of diabetes drug due to cancer causing chemical

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Borosilicate Glass Reactor

1-(3-METHYL-1-PHENYL-5-PYRAZOLYL)PIPERAZINE

2 '- Deoxycytidine

2 '- Deoxyuridine

Steviol Glycosides Reb I

Steviol Glycosides Reb E

Marksans Pharma recalls 11,279 bottles of diabetes drug due to cancer causing chemical

expresspharmaJune 11, 2020

Tag: Marksans Pharma , Metformin extended release tablets , NDMA , Diabetes

Favorites

Marksans Pharma said it is recalling 11,279 bottles of diabetes drug Metformin extended release tablets due to presence of a cancer causing contaminant.

The company has issued voluntary recall of one batch of Metformin extended release tablets (USP 500 mg) due to detection of NDMA (N-nitrosodimethylamine), Marksans Pharma said in a regulatory filing.

The recalled batch contains 11,279 bottles, it added. Metformin extended release tablets are indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus.

Previous:Government lifts export restrictions on HCQ APIs, formulations

Next:Dr Reddy’s Laboratories completes acquisition of Wockhardt’s select business divisions

Alzheimer’s Disease: Charting the Course from Plaques to Promise

Muhammad Farhan KhalidMay 28, 2025

New Tools，New Hope，New Frontier

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

PharmaSourcesMay 16, 2025

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

PR NewswireMay 12, 2025

Marksans Pharma recalls 11,279 bottles of diabetes drug due to cancer causing chemical | Pharmasources.com

Illuccix China Phase 3 Study Completes Enrolment

PR NewswireMay 13, 2025

Telix Pharmaceuticals Limited announces that the pivotal Phase 3 registration study of TLX591-CDx for prostate cancer imaging in Chinese patients has completed patient enrolment.

free性video西欧极品,伊人依成久久人综合网,中文字幕人妻一区二区三区熟女,男女高潮激烈无遮挡免费观软件 ,成人3d动漫一区二区三区

Marksans Pharma recalls 11,279 bottles of diabetes drug due to cancer causing chemical

Related News

Alzheimer’s Disease: Charting the Course from Plaques to Promise

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

Illuccix China Phase 3 Study Completes Enrolment

You may like
More>>

free性video西欧极品,伊人依成久久人综合网,中文字幕人妻一区二区三区熟女,男女高潮激烈无遮挡免费观软件 ,成人3d动漫一区二区三区

Marksans Pharma recalls 11,279 bottles of diabetes drug due to cancer causing chemical

Related News

Alzheimer’s Disease: Charting the Course from Plaques to Promise

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

Illuccix China Phase 3 Study Completes Enrolment

You may likeMore>>

You may like
More>>